Go to main text Go to main menu

Professionals

Professionals

이영일.png
Young Il Lee
Patent Attorney / Partner
  • +82-2-6677-7603
  • yilee@jjpat.com

Practice Areas

Bio/Chemistry/Trademark/Design

Education and
Qualifications

  • B.S. in Pharmaceutical Sciences, Seoul National University
  • Passed the 37th Patent Attorney Examination (2000)
  • ICVS (International Certified Valuation Specialist) (2012)
  • Licensed Pharmacist (1998)

Career

Current)
  • Partner Patent Attorney, JUNGJIN Patent & Law Firm
Previous)
  • Patent Attorney, Lee International IP & Law Group
  • Partner Patent Attorney, WooIn Patent & Law Firm
  • Head of Patent Team, Hanwha Solutions Corporation (formerly Hanwha Chemical Corporation)
  • Head of Legal and IP Department, Genexine, Inc.
  • Patent Attorney, R&D Business Division, Asan Medical Center, Seoul
  • Head of R&BD Strategy and Planning Division, Wellmarker Bio Co., Ltd.
  • Head of Business Development Division, Recerise Therapeutics, Inc.

Bailiwick

Biotechnology / Pharmacy

Key achievements

  • Provided Korean published patent gazette domain services for Korean pharmaceutical companies to Israeli pharmaceutical company T
  • Advised the Korean Intellectual Property Office (KIPO) on the revision of examination guidelines in the pharmaceutical sector
  • Prepared a patent map for an antibody development project for domestic pharmaceutical company G
  • Conducted patent rights analysis for ETRI’s “Ubiquitous Health Monitoring System” project
  • Prepared a patent map for GIST’s seawater desalination technology development project
  • Developed a design-around strategy and handled a passive scope confirmation trial regarding a polymorph patent for Company H
  • Built a patent portfolio related to medical devices for Company C
  • Drafted a business execution plan and established a patent strategy for multi-component materials for the Gene Donguibogam Project Group
  • Conducted a technology valuation for new therapeutic uses of DPP-4 inhibitors for Foundation A and Company D
  • Performed a Freedom to Operate (FTO) analysis related to biosimilars for Company A